The IGF-1R/InsR signaling as an anti-tumor target has accordingly been studied in preclinical NSCLC models using either small molecule inhibitors towards the kinase domain or IGF-1R/InsR targeting antibodies [14-16, 19-24]. This evidence concerns the gene IGF1R and neoplasm.